author_facet Whangbo, Jennifer S.
Kim, Haesook T.
Nikiforow, Sarah
Koreth, John
Alho, Ana C.
Falahee, Bryn
Kim, Soomin
Dusenbury, Katharine
Fields, Marie J.
Reynolds, Carol G.
Alyea, Edwin P.
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
Whangbo, Jennifer S.
Kim, Haesook T.
Nikiforow, Sarah
Koreth, John
Alho, Ana C.
Falahee, Bryn
Kim, Soomin
Dusenbury, Katharine
Fields, Marie J.
Reynolds, Carol G.
Alyea, Edwin P.
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
author Whangbo, Jennifer S.
Kim, Haesook T.
Nikiforow, Sarah
Koreth, John
Alho, Ana C.
Falahee, Bryn
Kim, Soomin
Dusenbury, Katharine
Fields, Marie J.
Reynolds, Carol G.
Alyea, Edwin P.
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
spellingShingle Whangbo, Jennifer S.
Kim, Haesook T.
Nikiforow, Sarah
Koreth, John
Alho, Ana C.
Falahee, Bryn
Kim, Soomin
Dusenbury, Katharine
Fields, Marie J.
Reynolds, Carol G.
Alyea, Edwin P.
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
Blood Advances
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
Hematology
author_sort whangbo, jennifer s.
spelling Whangbo, Jennifer S. Kim, Haesook T. Nikiforow, Sarah Koreth, John Alho, Ana C. Falahee, Bryn Kim, Soomin Dusenbury, Katharine Fields, Marie J. Reynolds, Carol G. Alyea, Edwin P. Armand, Philippe Cutler, Corey S. Ho, Vincent T. Antin, Joseph H. Soiffer, Robert J. Ritz, Jerome 2473-9529 2473-9537 American Society of Hematology Hematology http://dx.doi.org/10.1182/bloodadvances.2018027474 <jats:title>Abstract</jats:title><jats:p>Patients with chronic graft-versus-host disease (cGVHD) have a paucity of regulatory CD4 T cells (CD4Tregs) that mediate peripheral tolerance. In clinical trials, daily low-dose interleukin-2 (IL-2) has been administered safely for prolonged periods in patients with steroid-refractory cGVHD. Peripheral CD4Tregs expand dramatically in all patients during IL-2 therapy but clinical improvement was observed in ∼50% of patients. Here, we examined the impact of low-dose IL-2 therapy on functional T-cell markers and the T-cell repertoire within CD4Tregs, conventional CD4 T cells (CD4Tcons), and CD8+ T cells. IL-2 had profound effects on CD4Tregs homeostasis in both response groups including selective expansion of the naive subset, improved thymic output, and increased expression of Ki67, FOXP3, and B-cell lymphoma 2 within CD4Tregs. Similar changes were not seen in CD4Tcons or CD8 T cells. Functionally, low-dose IL-2 enhanced, in vitro, CD4Treg-suppressive activity in both response groups, and all patient CD4Tcons were similarly suppressed by healthy donor CD4Tregs. High-throughput sequencing of the T-cell receptor β (TCRβ) locus demonstrated that low-dose IL-2 therapy increased TCR repertoire diversity and decreased evenness within CD4Tregs without affecting CD4Tcons or CD8 T cells. Using clone-tracking analysis, we observed rapid turnover of highly prevalent clones in CD4Tregs as well as the conversion of CD4Tcons to CD4Tregs. After 12 weeks of daily IL-2, clinical responders had a greater influx of novel clones within the CD4Treg compartment compared with nonresponders. Further studies to define the function and specificity of these novel CD4Treg clones may help establish the mechanisms whereby low-dose IL-2 therapy promotes immune tolerance.</jats:p> Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease Blood Advances
doi_str_mv 10.1182/bloodadvances.2018027474
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTgwMjc0NzQ
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTgwMjc0NzQ
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Rs1
DE-Pl11
DE-105
DE-14
DE-Ch1
DE-L229
imprint American Society of Hematology, 2019
imprint_str_mv American Society of Hematology, 2019
issn 2473-9529
2473-9537
issn_str_mv 2473-9529
2473-9537
language English
mega_collection American Society of Hematology (CrossRef)
match_str whangbo2019functionalanalysisofclinicalresponsetolowdoseil2inpatientswithrefractorychronicgraftversushostdisease
publishDateSort 2019
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood Advances
source_id 49
title Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_unstemmed Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_full Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_fullStr Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_full_unstemmed Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_short Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_sort functional analysis of clinical response to low-dose il-2 in patients with refractory chronic graft-versus-host disease
topic Hematology
url http://dx.doi.org/10.1182/bloodadvances.2018027474
publishDate 2019
physical 984-994
description <jats:title>Abstract</jats:title><jats:p>Patients with chronic graft-versus-host disease (cGVHD) have a paucity of regulatory CD4 T cells (CD4Tregs) that mediate peripheral tolerance. In clinical trials, daily low-dose interleukin-2 (IL-2) has been administered safely for prolonged periods in patients with steroid-refractory cGVHD. Peripheral CD4Tregs expand dramatically in all patients during IL-2 therapy but clinical improvement was observed in ∼50% of patients. Here, we examined the impact of low-dose IL-2 therapy on functional T-cell markers and the T-cell repertoire within CD4Tregs, conventional CD4 T cells (CD4Tcons), and CD8+ T cells. IL-2 had profound effects on CD4Tregs homeostasis in both response groups including selective expansion of the naive subset, improved thymic output, and increased expression of Ki67, FOXP3, and B-cell lymphoma 2 within CD4Tregs. Similar changes were not seen in CD4Tcons or CD8 T cells. Functionally, low-dose IL-2 enhanced, in vitro, CD4Treg-suppressive activity in both response groups, and all patient CD4Tcons were similarly suppressed by healthy donor CD4Tregs. High-throughput sequencing of the T-cell receptor β (TCRβ) locus demonstrated that low-dose IL-2 therapy increased TCR repertoire diversity and decreased evenness within CD4Tregs without affecting CD4Tcons or CD8 T cells. Using clone-tracking analysis, we observed rapid turnover of highly prevalent clones in CD4Tregs as well as the conversion of CD4Tcons to CD4Tregs. After 12 weeks of daily IL-2, clinical responders had a greater influx of novel clones within the CD4Treg compartment compared with nonresponders. Further studies to define the function and specificity of these novel CD4Treg clones may help establish the mechanisms whereby low-dose IL-2 therapy promotes immune tolerance.</jats:p>
container_issue 7
container_start_page 984
container_title Blood Advances
container_volume 3
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792345379890528260
geogr_code not assigned
last_indexed 2024-03-01T17:22:13.231Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Functional+analysis+of+clinical+response+to+low-dose+IL-2+in+patients+with+refractory+chronic+graft-versus-host+disease&rft.date=2019-04-09&genre=article&issn=2473-9537&volume=3&issue=7&spage=984&epage=994&pages=984-994&jtitle=Blood+Advances&atitle=Functional+analysis+of+clinical+response+to+low-dose+IL-2+in+patients+with+refractory+chronic+graft-versus-host+disease&aulast=Ritz&aufirst=Jerome&rft_id=info%3Adoi%2F10.1182%2Fbloodadvances.2018027474&rft.language%5B0%5D=eng
SOLR
_version_ 1792345379890528260
author Whangbo, Jennifer S., Kim, Haesook T., Nikiforow, Sarah, Koreth, John, Alho, Ana C., Falahee, Bryn, Kim, Soomin, Dusenbury, Katharine, Fields, Marie J., Reynolds, Carol G., Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome
author_facet Whangbo, Jennifer S., Kim, Haesook T., Nikiforow, Sarah, Koreth, John, Alho, Ana C., Falahee, Bryn, Kim, Soomin, Dusenbury, Katharine, Fields, Marie J., Reynolds, Carol G., Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Whangbo, Jennifer S., Kim, Haesook T., Nikiforow, Sarah, Koreth, John, Alho, Ana C., Falahee, Bryn, Kim, Soomin, Dusenbury, Katharine, Fields, Marie J., Reynolds, Carol G., Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome
author_sort whangbo, jennifer s.
container_issue 7
container_start_page 984
container_title Blood Advances
container_volume 3
description <jats:title>Abstract</jats:title><jats:p>Patients with chronic graft-versus-host disease (cGVHD) have a paucity of regulatory CD4 T cells (CD4Tregs) that mediate peripheral tolerance. In clinical trials, daily low-dose interleukin-2 (IL-2) has been administered safely for prolonged periods in patients with steroid-refractory cGVHD. Peripheral CD4Tregs expand dramatically in all patients during IL-2 therapy but clinical improvement was observed in ∼50% of patients. Here, we examined the impact of low-dose IL-2 therapy on functional T-cell markers and the T-cell repertoire within CD4Tregs, conventional CD4 T cells (CD4Tcons), and CD8+ T cells. IL-2 had profound effects on CD4Tregs homeostasis in both response groups including selective expansion of the naive subset, improved thymic output, and increased expression of Ki67, FOXP3, and B-cell lymphoma 2 within CD4Tregs. Similar changes were not seen in CD4Tcons or CD8 T cells. Functionally, low-dose IL-2 enhanced, in vitro, CD4Treg-suppressive activity in both response groups, and all patient CD4Tcons were similarly suppressed by healthy donor CD4Tregs. High-throughput sequencing of the T-cell receptor β (TCRβ) locus demonstrated that low-dose IL-2 therapy increased TCR repertoire diversity and decreased evenness within CD4Tregs without affecting CD4Tcons or CD8 T cells. Using clone-tracking analysis, we observed rapid turnover of highly prevalent clones in CD4Tregs as well as the conversion of CD4Tcons to CD4Tregs. After 12 weeks of daily IL-2, clinical responders had a greater influx of novel clones within the CD4Treg compartment compared with nonresponders. Further studies to define the function and specificity of these novel CD4Treg clones may help establish the mechanisms whereby low-dose IL-2 therapy promotes immune tolerance.</jats:p>
doi_str_mv 10.1182/bloodadvances.2018027474
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTgwMjc0NzQ
imprint American Society of Hematology, 2019
imprint_str_mv American Society of Hematology, 2019
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229
issn 2473-9529, 2473-9537
issn_str_mv 2473-9529, 2473-9537
language English
last_indexed 2024-03-01T17:22:13.231Z
match_str whangbo2019functionalanalysisofclinicalresponsetolowdoseil2inpatientswithrefractorychronicgraftversushostdisease
mega_collection American Society of Hematology (CrossRef)
physical 984-994
publishDate 2019
publishDateSort 2019
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood Advances
source_id 49
spelling Whangbo, Jennifer S. Kim, Haesook T. Nikiforow, Sarah Koreth, John Alho, Ana C. Falahee, Bryn Kim, Soomin Dusenbury, Katharine Fields, Marie J. Reynolds, Carol G. Alyea, Edwin P. Armand, Philippe Cutler, Corey S. Ho, Vincent T. Antin, Joseph H. Soiffer, Robert J. Ritz, Jerome 2473-9529 2473-9537 American Society of Hematology Hematology http://dx.doi.org/10.1182/bloodadvances.2018027474 <jats:title>Abstract</jats:title><jats:p>Patients with chronic graft-versus-host disease (cGVHD) have a paucity of regulatory CD4 T cells (CD4Tregs) that mediate peripheral tolerance. In clinical trials, daily low-dose interleukin-2 (IL-2) has been administered safely for prolonged periods in patients with steroid-refractory cGVHD. Peripheral CD4Tregs expand dramatically in all patients during IL-2 therapy but clinical improvement was observed in ∼50% of patients. Here, we examined the impact of low-dose IL-2 therapy on functional T-cell markers and the T-cell repertoire within CD4Tregs, conventional CD4 T cells (CD4Tcons), and CD8+ T cells. IL-2 had profound effects on CD4Tregs homeostasis in both response groups including selective expansion of the naive subset, improved thymic output, and increased expression of Ki67, FOXP3, and B-cell lymphoma 2 within CD4Tregs. Similar changes were not seen in CD4Tcons or CD8 T cells. Functionally, low-dose IL-2 enhanced, in vitro, CD4Treg-suppressive activity in both response groups, and all patient CD4Tcons were similarly suppressed by healthy donor CD4Tregs. High-throughput sequencing of the T-cell receptor β (TCRβ) locus demonstrated that low-dose IL-2 therapy increased TCR repertoire diversity and decreased evenness within CD4Tregs without affecting CD4Tcons or CD8 T cells. Using clone-tracking analysis, we observed rapid turnover of highly prevalent clones in CD4Tregs as well as the conversion of CD4Tcons to CD4Tregs. After 12 weeks of daily IL-2, clinical responders had a greater influx of novel clones within the CD4Treg compartment compared with nonresponders. Further studies to define the function and specificity of these novel CD4Treg clones may help establish the mechanisms whereby low-dose IL-2 therapy promotes immune tolerance.</jats:p> Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease Blood Advances
spellingShingle Whangbo, Jennifer S., Kim, Haesook T., Nikiforow, Sarah, Koreth, John, Alho, Ana C., Falahee, Bryn, Kim, Soomin, Dusenbury, Katharine, Fields, Marie J., Reynolds, Carol G., Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Blood Advances, Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease, Hematology
title Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_full Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_fullStr Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_full_unstemmed Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_short Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
title_sort functional analysis of clinical response to low-dose il-2 in patients with refractory chronic graft-versus-host disease
title_unstemmed Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
topic Hematology
url http://dx.doi.org/10.1182/bloodadvances.2018027474